Clinical Trial Update: Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent

View source ↗

Summary

This completed clinical trial evaluated bone mineral loss in prostate cancer patients treated with a GnRH agonist alone versus GnRH agonist plus an anti-androge…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Anti-androgen agent (Anti-androgen)
• GnRH agonist (gonadotropin-releasing hormone agonist)

Snippet

Sponsor: AstraZeneca | Conditions: GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients | Status: COMPLETED